Tsai TF - Search Results

1

Clinical advances in biological therapy for generalized pustular psoriasis: a review.

Hsieh CY, Tsai TF. Hsieh CY, et al. Among authors: tsai tf. Expert Opin Biol Ther. 2024 Jan-Feb;24(1-2):37-50. doi: 10.1080/14712598.2024.2309301. Epub 2024 Feb 4. Expert Opin Biol Ther. 2024. PMID: 38247394 Review.

2

Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: A case report and review of published work.

Ho PH, Tsai TF. Ho PH, et al. Among authors: tsai tf. J Dermatol. 2018 Nov;45(11):1353-1356. doi: 10.1111/1346-8138.14636. Epub 2018 Sep 19. J Dermatol. 2018. PMID: 30230584 Review.

3

Remission Duration and Long-Term Outcomes in Patients with Moderate-to-Severe Psoriasis Treated by Biologics or Tofacitinib in Controlled Clinical Trials: A 15-Year Single-Center Experience.

Huang YW, Tsai TF. Huang YW, et al. Among authors: tsai tf. Dermatol Ther (Heidelb). 2019 Sep;9(3):553-569. doi: 10.1007/s13555-019-0310-5. Epub 2019 Jul 3. Dermatol Ther (Heidelb). 2019. PMID: 31270683 Free PMC article.

4

A review of antibiotics and psoriasis: induction, exacerbation, and amelioration.

Tsai YC, Tsai TF. Tsai YC, et al. Among authors: tsai tf. Expert Rev Clin Pharmacol. 2019 Oct;12(10):981-989. doi: 10.1080/17512433.2019.1665027. Epub 2019 Sep 30. Expert Rev Clin Pharmacol. 2019. PMID: 31498683 Review.

5

Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study.

Chiu HY, Chiu YM, Chang Liao NF, Chi CC, Tsai TF, Hsieh CY, Hsieh TY, Lai KL, Chiu TM, Wu NL, Hui RC, Lee CN, Wang TS, Chen PH, Yang CC, Huang YH. Chiu HY, et al. Among authors: tsai tf. J Am Acad Dermatol. 2021 Aug;85(2):337-344. doi: 10.1016/j.jaad.2019.12.001. Epub 2019 Dec 9. J Am Acad Dermatol. 2021. PMID: 31821860

6

Pharmacological Management of Pediatric Pustular Psoriasis.

Huang YW, Tsai TF. Huang YW, et al. Among authors: tsai tf. Paediatr Drugs. 2020 Jun;22(3):265-277. doi: 10.1007/s40272-020-00383-6. Paediatr Drugs. 2020. PMID: 32020425

7

A drug safety evaluation of risankizumab for psoriasis.

Huang YW, Tsai TF. Huang YW, et al. Among authors: tsai tf. Expert Opin Drug Saf. 2020 Apr;19(4):395-402. doi: 10.1080/14740338.2020.1736034. Epub 2020 Mar 5. Expert Opin Drug Saf. 2020. PMID: 32100591 Review.

8

Switching biologics in psoriasis - practical guidance and evidence to support.

Tsai YC, Tsai TF. Tsai YC, et al. Among authors: tsai tf. Expert Rev Clin Pharmacol. 2020 May;13(5):493-503. doi: 10.1080/17512433.2020.1767590. Epub 2020 May 27. Expert Rev Clin Pharmacol. 2020. PMID: 32394765 Review.

9

Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review.

Hsieh CY, Tsai TF. Hsieh CY, et al. Among authors: tsai tf. Clin Drug Investig. 2020 Oct;40(10):915-926. doi: 10.1007/s40261-020-00956-w. Clin Drug Investig. 2020. PMID: 32691244 Review.

10

Treatment Response of Patients with Erythrodermic Psoriasis after Switching to Guselkumab.

Chiang CY, Tsai TF. Chiang CY, et al. Among authors: tsai tf. Dermatol Ther (Heidelb). 2021 Feb;11(1):301-306. doi: 10.1007/s13555-020-00480-x. Epub 2021 Feb 3. Dermatol Ther (Heidelb). 2021. PMID: 33400156 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

539 results

Search Page